Study wrapper · #1032
Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis.
Zeng L, Zinmon-Htet C, Hundie T, et al. Annals of the American Thoracic Society. 2026.
DOI: 10.1093/annalsats/aaoag177PubMed: 42479131
Editor's note
A systematic review and meta-analysis of 123 studies assessing respiratory adverse events of weight-loss medications, including semaglutide and tirzepatide. The pooled randomized-trial data, judged at low risk of bias, showed no signal of increased respiratory harm versus placebo, though evidence specific to people with asthma was sparse. This is a reassuring, well-conducted synthesis on a focused safety question.
Plain-language abstract
This systematic review and meta-analysis of 123 studies found that semaglutide, tirzepatide, and liraglutide were not associated with increased respiratory adverse events compared with placebo. Common events like nasopharyngitis occurred but were not linked to the drugs specifically.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026